TY - JOUR
T1 - Perlecan heparan sulfate deficiency impairs pulmonary vascular development and attenuates hypoxic pulmonary hypertension.
AU - Chang, Ya-Ting
AU - Tseng, Chi-Nan
AU - Tannenberg, Philip
AU - Eriksson, Linnéa
AU - Yuan, Ke
AU - de Jesus Perez, Vinicio A
AU - Lundberg, Johan
AU - Lengquist, Mariette
AU - Botusan, Ileana Ruxandra
AU - Catrina, Sergiu-Bogdan
AU - Tran, Phan-Kiet
AU - Hedin, Ulf
AU - Tran Lundmark, Karin
PY - 2015
Y1 - 2015
N2 - Excessive vascular cell proliferation is an important component of pulmonary hypertension (PH). Perlecan is the major heparan sulfate (HS) proteoglycan in the vascular extracellular matrix. It binds growth factors, including FGF2, and either restricts or promotes cell proliferation. In this study, we have explored the effects of perlecan HS deficiency on pulmonary vascular development and in hypoxia-induced PH.
AB - Excessive vascular cell proliferation is an important component of pulmonary hypertension (PH). Perlecan is the major heparan sulfate (HS) proteoglycan in the vascular extracellular matrix. It binds growth factors, including FGF2, and either restricts or promotes cell proliferation. In this study, we have explored the effects of perlecan HS deficiency on pulmonary vascular development and in hypoxia-induced PH.
U2 - 10.1093/cvr/cvv143
DO - 10.1093/cvr/cvv143
M3 - Article
C2 - 25952902
SN - 1755-3245
VL - 107
SP - 20
EP - 31
JO - Cardiovascular Research
JF - Cardiovascular Research
IS - 1
ER -